艾考糊精通过其类似“胶体”渗透压的机制，应用于腹膜透析的长保留阶段并形成有效的超滤。在经典的基于艾考糊精透析液的治疗方案基础上，出现了每日单次使用艾考糊精透析液、每日2次使用艾考糊精透析液、艾考糊精与葡萄糖腹膜透析液联合等多种治疗方案，适用于不同的临床状况中。艾考糊精腹膜透析液的应用，有助于控制慢性心力衰竭，改善或维持心室结构。应用基于艾考糊精透析液的治疗方案将会有效地提升我国腹膜透析治疗的水平。
codextrin through a mechanism resembling ‘colloid’ osmosis forms effective ultrafiltration during the long dwelling phase of peritoneal dialysate. On the basis of the classic icodextrin dialysate-based treatment regimen, a variety of treatment schedules suitable for different clinical conditions have been developed, such as single daily use of icodextrin dialysate, twice daily use of icodextrin dialysate, and icodextrin combined with glucose peritoneal dialysate. Icodextrin dialysate can help control chronic heart failure and improve or maintain ventricular structure. The treatment regimen based on icodextrin dialysate will effectively improve our peritoneal dialysis treatment.
[1] Rangaswamy D, Guddattu V, Webster AC, et al. Icodextrin use for peritoneal dialysis in Australia: A cohort study using Australia and New Zealand Dialysis and Transplant Registry [J]. Perit Dial Int. 2020,40(2):209-219.
[2] Frampton JE, Plosker GL. Icodextrin: a review of its use in peritoneal dialysis [J]. Drugs. 2003,63(19):2079-2105.
[3] Heimbürger O. Peritoneal transport with icodextrin solution [J]. Contrib Nephrol. 2006;150:97-103.
[4] Dousdampanis P, Musso CG, Trigka K. Icodextrin and peritoneal dialysis: advantages and new applications [J]. Int Urol Nephrol. 2018,50(3):495-500.
[5] Olszowska A, Waniewski J, Stachowska-Pietka J, et al. Long Peritoneal Dialysis Dwells With Icodextrin: Kinetics of Transperitoneal Fluid and Polyglucose Transport [J]. Front Physiol. 2019,10:1326.
[6] Lin A, Qian J, Li X, et al. Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid [J]. Clin J Am Soc Nephrol. 2009,4(11):1799-804
[7] Agar BU, Sloand JA. Single Daily Icodextrin Exchange as Initial and Solitary Therapy [J]. Perit Dial Int. 2018,38(2):119-124.
[8] Goossen K, Becker M, Marshall MR, et al. Icodextrin Versus Glucose Solutions for the Once-Daily Long Dwell in Peritoneal Dialysis: An Enriched Systematic Review and Meta-analysis of Randomized Controlled Trials [J]. Am J Kidney Dis. 2020,75(6):830-846.
[9] Dousdampanis P, Trigka K, Chu M, et al. Two icodextrin exchanges per day in peritoneal dialysis patients with ultrafiltration failure: one center's experience and review of the literature [J]. Int Urol Nephrol. 2011,43(1):203-209.
[10] Ballout A,?Garcia-Lopez E,?Struyven J, et al.Double-dose icodextrin to increase ultrafiltration in PD patients with inadequate ultrafiltration [J]. Perit Dial Int. 2011, 31(1):91-94
[11] Peers E. Icodextrin plus glucose combinations for use in CAPD [J]. Perit Dial Int. 1997,17 Suppl 2:S68-S69.
[12] Morelle J, Sow A, Fustin CA, et al. Mechanisms of Crystalloid versus Colloid Osmosis across the Peritoneal Membrane [J]. J Am Soc Nephrol. 2018,29(7):1875-1886.
[13] Freida P, Galach M, Divino Filho JC, et al. Combination of crystalloid (glucose) and colloid (icodextrin) osmotic agents markedly enhances peritoneal fluid and solute transport during the long PD dwell [J]. Perit Dial Int. 2007,27(3):267-76.
[14] Dallas F, Jenkins SB, Wilkie ME. Enhanced ultrafiltration using 7.5% icodextrin/1.36% glucose combination dialysate: a pilot study [J]. Perit Dial Int. 2004,24(6):542-6.
[15] Chen JB, Cheng BC, Liu WH, et al. Longitudinal analysis of cardiac structure and function in incident-automated peritoneal dialysis: comparison between icodextrin solution and glucose-based solution [J]. BMC Nephrol. 2018,8;19(1):109.
[16] Yeoungjee Cho,?David W Johnson,?Sunil Badve,?et al. Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials [J]. Nephrol Dial Transplant. 2013,28:1899–1907
[17] Sánchez JE, Ortega T, Rodríguez C,?et al. Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure [J]. Nephrol Dial Transplant. 2010,25(2):605-610.
[18] Bertoli SV,?Musetti C,?Ciurlino D, et al. Peritoneal ultrafiltration in refractory heart failure: a cohort study [J]. Perit Dial Int. 2014,34(1):64-70.
[19] Sav T,?Inanc MT,?Dogan A, et al. Two daytime icodextrin exchanges decrease brain natriuretic peptide levels and improve cardiac functions in continuous ambulatory peritoneal dialysis patients [J]. Nephrology (Carlton). 2010,15(3):307-312.
[20] Kunin M,?Ganon L,?Holtzman EJ, et al. ?Hyponatremia in refractory congestive heart failure patients treated with icodextrin-based peritoneal dialysis: A case series [J]. Nefrologia (Engl Ed). 2018,38(1):87-91.
[21] Gokal R,?Moberly J,?Lindholm B,?et al. Metabolic and laboratory effects of icodextrin [J]. Kidney Int Suppl. 2002,(81):S62-S71.
[22] Wang IK, Li YF, Chen JH, et al. Icodextrin decreases technique failure and improves patient survival in peritoneal dialysis patients [J]. Nephrology (Carlton). 2015,20(3):161-167.
